EUVIMEDEUVIMED entdecken
Crossref

Development of SARS-CoV-2 papain-like protease inhibitors with a thiadiazole and oxadiazole linker

Rafaqat Hussain, Hina Sarfraz, Tahir Ali Chohan, Uzma Azam, Umair Khurshid, Shoaib Khan, Yazeed M. Asiri, Saeed Anwar

Pure and Applied Chemistry · 10.08.2026

DOI: 10.1515/pac-2026-0807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pure and Applied Chemistry, online erschienen am 10.08.2026. Verfasst von Rafaqat Hussain und 7 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing prevalence of SARS-CoV-2 variations highlights the urgent need for novel antiviral agents targeting key viral proteins. The papain-like protease (PLpro) is pivotal in viral replication and immune evasion, rendering it a compelling therapeutic target. In the present study, a series of novel thiadiazole- and oxadiazole-based derivatives (12-g & 13a-g) were rationally designed based on the structural features of the known PLpro inhibitor GRL0617. Convergent synthetic strategy was employed to synthesize the target compounds involving the construction of 1,3,4-thiadiazole/oxadiazole intermediates followed by amide coupling with a naphthyl-containing scaffold. All compounds were characterized by 1 H NHMR, 13 C NMR and mass spectrometry and evaluated for their in vitro SARS-CoV-2 PLpro inhibitory activity. Several compounds exhibited potent inhibition, surpassing the reference inhibitor GRL0617 (IC 50 = 2.4 ± 1.1 µM). Among them, oxadiazole derivative (13c) featuring 3-cyanophenyl substitution emerged as the most potent inhibitor with IC 50 value of 0.06 ± 0.8 µM, followed by compounds (12b, IC 50 = 0.3 ± 0.3 µM), (12e, IC 50 = 0.4 ± 1.6 µM) and (13e, IC 50 = 0.6 ± 0.8 µM) respectively. Structure activity relationship (SAR) analysis revealed that electron-withdrawing substituents, particularly cyano group at meta position, significantly enhanced PLpro inhibition whereas methoxy/methyl groups resulted in reduced inhibition. Furthermore, molecular docking studies demonstrated favorable binding interactions of the compounds within the PLpro catalytic pocket through H-bonding, hydrophobic and π–π interactions. Moreover, molecular dynamic simulations confirmed the stability of the ligand-protein complexes throughout the simulation period supporting the experimental findings. The integrated rational design-based synthesis, biological evaluation, and computational investigations collectively identified thiadiazole/oxadiazole scaffolds as promising candidates for the development of SARS-CoV-2 inhibitors, offering valuable insights for next-generation antiviral agents targeting coronavirus proteases.

Zitieren

APA

Hussain, R., Sarfraz, H., Chohan, T. A., Azam, U., Khurshid, U., Khan, S., Asiri, Y. M., & Anwar, S. (2026). Development of SARS-CoV-2 papain-like protease inhibitors with a thiadiazole and oxadiazole linker. Pure and Applied Chemistry. https://doi.org/10.1515/pac-2026-0807

Vancouver

Hussain R, Sarfraz H, Chohan TA, Azam U, Khurshid U, Khan S, et al. Development of SARS-CoV-2 papain-like protease inhibitors with a thiadiazole and oxadiazole linker. Pure and Applied Chemistry. 2026. doi:10.1515/pac-2026-0807

BibTeX
@article{Hussain2026,
  author = {Hussain, Rafaqat and Sarfraz, Hina and Chohan, Tahir Ali and Azam, Uzma and Khurshid, Umair and Khan, Shoaib and Asiri, Yazeed M. and Anwar, Saeed},
  title = {Development of SARS-CoV-2 papain-like protease inhibitors with a thiadiazole and oxadiazole linker},
  journal = {Pure and Applied Chemistry},
  year = {2026},
  doi = {10.1515/pac-2026-0807}
}
Kostenlos starten →